scispace - formally typeset
Journal ArticleDOI

The interferon signature in autoimmune diseases.

Lars Rönnblom, +1 more
- 01 Mar 2013 - 
- Vol. 25, Iss: 2, pp 248-253
Reads0
Chats0
TLDR
The observed IFN signature in several autoimmune diseases is a biomarker of active disease and is investigated as a tool when selecting treatment for individual patients.
Abstract
Purpose of reviewAn increased expression of type I interferon (IFN) regulated genes (an IFN signature) has been reported in blood and tissue cells from patients with SLE and other autoimmune diseases. We review the possible mechanisms behind the IFN signature as well as clinical and therapeutic cons

read more

Citations
More filters
Journal ArticleDOI

Disturbed natural killer cell homeostasis in the salivary gland enhances autoimmune pathology via IFN-γ in a mouse model of primary Sjögren’s syndrome

TL;DR: Results indicate that SG cNK cells may enhance the autoreactive response in the target organ by upregulating of IFN-γ, whereas SG rNK cells protect target cells against T cell cytotoxicity.
Journal ArticleDOI

Expression of PD-1, PD-L1 and PD-L2 in Lymphomas in Patients with Pre-Existing Rheumatic Diseases—A Possible Association with High Rheumatoid Arthritis Disease Activity

TL;DR: In patients with pre-existing rheumatoid arthritis and subsequent diffuse large B-cell lymphoma, an association between RA disease severity and increased expression of PD-L1 in tumor cells was seen and warrants further studies of the PD-1 pathway in lymphoma in other chronic inflammatory conditions.
Journal ArticleDOI

In Vitro Effects of Sulforaphane on Interferon-Driven Inflammation and Exploratory Evaluation in Two Healthy Volunteers.

TL;DR: In this paper, the contribution of sulforaphane (SFN), a cruciferous-derived bioactive molecule, in the modulation of interferon-driven inflammation in an immortalized human hepatocytes (IHH) line and in two healthy volunteers, focusing on STING, a key-component player in inter-feron pathway, inter-interferon signature modulation, and GSTM1 expression and genotype, which contributes to SFN metabolism and excretion.
Patent

Ppar agonist or lxr agonist for use in the treatment of systemic lupus erythematosus by modulation of lap activity

TL;DR: In this paper, compositions and methods are provided for modifying diagnosing and treating inflammatory disease. The methods and compositions can be used to ameliorate the effects of a deficiency in the LAP pathway for clearing dead cells.
References
More filters
Journal ArticleDOI

Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus

TL;DR: Global gene expression profiling of peripheral blood mononuclear cells is used to identify distinct patterns of gene expression that distinguish most SLE patients from healthy controls, and identify a subgroup of patients who may benefit from therapies targeting the IFN pathway.
Journal ArticleDOI

Interferon and Granulopoiesis Signatures in Systemic Lupus Erythematosus Blood

TL;DR: Microarray analysis of blood cells reveals that immature granulocytes may be involved in SLE pathogenesis, and the IFN signature confirms the central role of this cytokine in Sle, using oligonucleotide microarrays.
Journal ArticleDOI

JAK and STAT Signaling Molecules in Immunoregulation and Immune-Mediated Disease

TL;DR: Not only have genome-wide association studies demonstrated that this pathway is highly relevant to human autoimmunity, but targeting JAKs is now a reality in immune-mediated disease.
Related Papers (5)